Home › Wilms Tumor › Illinois › Chicago
Wilms Tumor clinical trials in Chicago, IL
4 studies for Wilms Tumor are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
RecruitingPhase 2
- University of Chicago Comprehensive Cancer Center, Chicago
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
RecruitingPhase 2
- Lurie Children's Hospital-Chicago, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RecruitingPhase 1/2
- Lurie Children's Hospital-Chicago, Chicago
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
RecruitingPhase 2
- Ann & Robert H. Lurie Children'S Hospital of Chicag, Chicago
About Wilms Tumor
Wilms' Tumor (or Nephroblastoma) is a rare type of cancer that affects one or both kidneys. Find a list of symptoms and treatments associated
More about Wilms Tumor on MedlinePlus
Wilms Tumor trials in other cities
- Washington, DC7 studies
- Memphis, TN6 studies
- Atlanta, GA5 studies
- Cincinnati, OH4 studies
- New York City, NY4 studies
- Mountain View, CA4 studies
- St. Louis, MO4 studies
- Los Angeles, CA4 studies
- Boston, MA4 studies
- Greenburgh, NY4 studies
- Houston, TX4 studies
- Philadelphia, PA4 studies
Other studies in Chicago
- Non-Small Cell Lung Cancer61 studies
- Breast Cancer58 studies
- Cancer (all types)51 studies
- Metastatic Cancer45 studies
- Prostate Cancer45 studies
- Obesity41 studies
- Lung Cancer41 studies
- Ovarian Cancer36 studies
- Stroke34 studies
- Colorectal Cancer33 studies
- Heart Failure31 studies
- Overweight28 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.